Title | Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Lawhn-Heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR |
Journal | Lancet Oncol |
Volume | 23 |
Issue | 2 |
Pagination | e75-e87 |
Date Published | 2022 02 |
ISSN | 1474-5488 |
Keywords | Humans, Liver Neoplasms, Male, Neoplasms, Neuroblastoma, Prostatic Neoplasms, Radioisotopes, Radiotherapy Dosage, Thyroid Neoplasms |
Abstract | Radionuclide therapy is a rapidly expanding oncological treatment method. Overwhelmingly, the application of radionuclide therapy in clinical practice relies on fixed or empirical dosing strategies. In principle, the application of dosimetry promises to improve patient outcomes by tailoring administered radionuclide therapy activities to each patient's unique tumour burden and tumour uptake. However, robust prospective data are scarce due to few prospective randomised clinical trials investigating the use of dosimetry in radionuclide therapy. In this Review, we describe the role of dosimetry as it has been applied historically and in modern clinical practice and its potential future applications. We further emphasise areas of future growth and a potential pathway to optimised personalised activity modulation of radionuclide therapy. |
DOI | 10.1016/S1470-2045(21)00657-4 |
Alternate Journal | Lancet Oncol |
PubMed ID | 35114134 |